Mechanistic DDI Risk with Oteseconazole: Insights from 2022 FDA Data

1. Study Background and Research Question

With the increasing complexity of polypharmacy and the introduction of novel antifungal agents, understanding drug-drug interaction (DDI) liabilities is essential to ensure therapeutic efficacy and safety. Regulatory agencies such as the US FDA now require systematic risk-based analysis of both enzyme- and transporter-mediated DDIs for all new drug approvals. Oteseconazole (VT-1161), a selective tetrazole CYP51 inhibitor, was approved in 2022 for the prevention of recurrent vulvovaginal candidiasis and management of Candida infections. Given its mechanism and intended use in populations frequently exposed to polypharmacy, the DDI potential of Oteseconazole is a critical concern for both clinicians and researchers (paper).

2. Key Innovation from the Reference Study

The reference study provides a systematic, mechanistic evaluation of DDI risk for all small molecule drugs approved by the FDA in 2022, including Oteseconazole. The innovation lies in the integration of in vitro inhibition/induction data, transporter profiling, and clinical pharmacokinetic outcomes to assess both the potential of new molecular entities to act as DDI perpetrators (affecting the metabolism/transport of other drugs) and victims (being affected by other drugs). The review also codifies how mechanistic findings are reflected in labeling and clinical recommendations, enhancing translational utility (paper).

3. Methods and Experimental Design Insights

The authors analyzed NDA review documents for 22 small molecule drugs approved by the FDA in 2022, extracting data on drug metabolism, transporter interactions, and DDI potential. Two standard predictive models were used for CYP-mediated and transporter-mediated DDI risk, following FDA DDI guidance (2020). The team characterized each drug as a substrate, inhibitor, or inducer of cytochrome P450 enzymes (notably CYP3A, CYP2C9, CYP2C19) and key transporters (such as P-gp and BCRP). Both in vitro (often using human liver microsomes, recombinant enzymes, or transporter-overexpressing cell lines) and clinical DDI studies with probe substrates/inhibitors informed the mechanistic classification (paper).

Protocol Parameters

• assay | 0.00625–0.1 μg/mL | In vitro antifungal susceptibility | Standard MIC determination for Candida spp. | product_spec
• assay | 65 μM (IC₅₀ for human CYP3A4) | In vitro CYP inhibition selectivity | Differentiates off-target effects on human P450s | product_spec
• assay | Use of P-gp/BCRP substrate/inhibitor assays | In vitro transporter DDI risk profiling | Identifies potential for clinically relevant transporter-mediated DDIs | paper
• assay | 10 mM Oteseconazole in DMSO stock | Compound preparation for cell-based and enzymatic assays | Ensures solubility/stability in antifungal research workflows | workflow_recommendation

4. Core Findings and Why They Matter

Enzyme-mediated DDI risk: Oteseconazole exhibits high selectivity for fungal CYP51, with minimal inhibition of human CYP enzymes, notably showing an IC₅₀ of 65 μM for CYP3A4, which is far less potent than many imidazole or triazole antifungals (product_spec). This selectivity minimizes the risk of clinically significant CYP-mediated DDIs when Oteseconazole is used concomitantly with CYP3A4 substrates (paper).

Transporter-mediated DDI risk: The analysis identified Oteseconazole as an inhibitor of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) in vitro. This places Oteseconazole among four 2022-approved drugs with notable transporter inhibition profiles. While transporter inhibition can theoretically increase plasma concentrations of co-administered P-gp/BCRP substrates, the magnitude of this effect in clinical scenarios depends on the therapeutic index of the affected agents and the magnitude of AUC changes observed. The study highlights that even moderate AUC increases (<2-fold) can trigger labeling recommendations, especially when co-medications have a narrow therapeutic index (paper).

Clinical implications: For antifungal agent for Candida infections, especially in recurrent vulvovaginal candidiasis, Oteseconazole’s selectivity profile supports its use in complex patient populations with reduced risk of CYP-mediated DDIs. However, careful consideration is warranted when co-administered with sensitive P-gp/BCRP substrates (e.g., certain immunosuppressants, chemotherapeutics), as per updated labeling recommendations. This nuanced risk assessment empowers clinicians and researchers to better anticipate and mitigate DDI risks in antifungal therapy (paper).

5. Comparison with Existing Internal Articles

The current analysis builds upon mechanistic insights described in several specialized internal resources. For example, the article "Oteseconazole (VT-1161): Mechanistic Precision in Antifungal Research" details the compound’s selectivity for fungal CYP51 and its implications for antifungal drug development, aligning with the reference study’s findings on DDI minimization and the rationale for advanced application in resistant Candida strains. Similarly, "Oteseconazole (VT-1161): Advanced Mechanistic Insights and Applications" discusses Oteseconazole’s translational relevance in recurrent vulvovaginal candidiasis and outlines workflow considerations that complement the DDI guidance provided in the FDA-wide review. These resources provide protocol-level recommendations for antifungal susceptibility testing and reinforce the reference paper’s call for context-specific DDI risk management in research and clinical practice.

6. Limitations and Transferability

While the review provides one of the most granular cross-drug DDI risk assessments for 2022 FDA approvals, some limitations exist. In vitro inhibition/induction and transporter data do not always translate directly to clinical outcomes, especially in the context of patient-specific variables (e.g., pharmacogenomics, co-morbidities). For Oteseconazole, the DDI risk with P-gp/BCRP substrates is primarily based on in vitro findings; further clinical pharmacokinetic studies may be warranted to clarify the true magnitude of interaction in diverse patient populations. Furthermore, the workflow protocols and DDI risk management strategies may require adaptation for non-standard patient groups (e.g., pediatric, immunocompromised) or for drugs not explicitly covered in the reviewed NDAs (paper).

Why this cross-domain matters, maturity, and limitations

The integration of DDI risk assessment with antifungal selectivity bridges clinical pharmacology and infectious disease management. This cross-domain approach is mature for CYP-mediated interactions (with robust labeling guidance), but less so for transporter interactions, where in vitro data may not predict clinical consequences with high precision. The findings for Oteseconazole are most actionable in the context of antifungal use for Candida infections and prevention of recurrent vulvovaginal candidiasis, with broader applicability contingent on further clinical validation.

7. Research Support Resources

To support researchers in implementing standardized antifungal susceptibility testing and DDI risk profiling, high-purity research compounds are essential. Oteseconazole (VT-1161) (SKU BA1665) is available from APExBIO for in vitro, cell-based, and protocol-driven antifungal studies. Its physicochemical properties and established selectivity profile make it suitable for modeling both antifungal efficacy and DDI risk in preclinical workflows. Investigators are encouraged to reference the reviewed FDA and protocol literature when designing or interpreting DDI-focused antifungal research.